+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 99Years
All Genders
ID07824297

NAIF 2.0 - COGNIFY Exploring Cognitive Impairment and Glymphatic Function Changes After Endovascular Treatment in Intracranial Dural Arteriovenous Fistula

Led by Hospital Universitari Vall d'Hebron Research Institute · Updated on 2026-09-17

20

Participants Needed

3

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are exploring whether intracranial dural arteriovenous fistulae dAVF, abnormal connections between arteries and veins in the brains covering, affect the brains waste-clearance system called the glymphatic system. This observational study aims to understand if the glymphatic systems function changes after routine endovascular embolization treatment of dAVF, focusing on the possible link between venous drainage issues and cognitive impairment. The study builds on previous findings suggesting that cognitive problems in dAVF patients may improve after treatment, but the underlying biological reasons remain unclear. Participants diagnosed with unruptured intracranial dAVF who are scheduled for endovascular embolization as part of their usual medical care will undergo advanced brain MRI scans at two time points before treatment and about six months afterward. The MRI protocol includes multiple imaging sequences, especially diffusion-weighted MRI techniques that assess glymphatic-related brain metrics such as DTI-ALPS, diffusion kurtosis imaging mean kurtosis DKI-MK, and free-water FW imaging. These measurements will help compare brain changes before and after embolization. During the study, participants will have two brain MRI sessions using a 3T scanner to capture detailed brain images related to glymphatic function. Researchers will analyze changes in the MRI-derived metrics to evaluate glymphatic system function and its potential recovery after treatment. The primary outcomes are changes in DTI-ALPS, MK, and FW values between baseline and six months post-treatment. This study may provide new insights into cognitive changes associated with dAVF and offer a better understanding of treatment effects beyond traditional risk factors. Participation involves imaging assessments with no experimental treatments beyond routine care.

CONDITIONS

Brief Title

NAIF 2.0 - COGNIFY

Research Team

L

Laura Ludovica Gramegna, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here